nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—PDGFRA—brain cancer	0.466	1	CbGaD
Ponatinib—CYP2D6—Lomustine—brain cancer	0.0323	0.17	CbGbCtD
Ponatinib—ABCG2—Carboplatin—brain cancer	0.0274	0.144	CbGbCtD
Ponatinib—CYP2D6—Hydroxyurea—brain cancer	0.0245	0.129	CbGbCtD
Ponatinib—CYP3A4—Temozolomide—brain cancer	0.0242	0.127	CbGbCtD
Ponatinib—ABCG2—Etoposide—brain cancer	0.023	0.121	CbGbCtD
Ponatinib—CYP3A4—Lomustine—brain cancer	0.0206	0.108	CbGbCtD
Ponatinib—CYP3A5—Etoposide—brain cancer	0.0127	0.067	CbGbCtD
Ponatinib—CYP2C8—Etoposide—brain cancer	0.0122	0.0644	CbGbCtD
Ponatinib—ABCB1—Etoposide—brain cancer	0.00829	0.0436	CbGbCtD
Ponatinib—CYP3A4—Etoposide—brain cancer	0.00497	0.0261	CbGbCtD
Ponatinib—FGFR3—skull—brain cancer	0.00464	0.0585	CbGeAlD
Ponatinib—FGFR2—skull—brain cancer	0.00304	0.0383	CbGeAlD
Ponatinib—FGFR4—Podofilox—Etoposide—brain cancer	0.00297	1	CbGdCrCtD
Ponatinib—FGFR4—hindbrain—brain cancer	0.00268	0.0338	CbGeAlD
Ponatinib—Nilotinib—PDGFRA—brain cancer	0.00162	0.362	CrCbGaD
Ponatinib—FGFR4—brainstem—brain cancer	0.00154	0.0194	CbGeAlD
Ponatinib—Imatinib—PDGFRA—brain cancer	0.00135	0.302	CrCbGaD
Ponatinib—TEK—endothelium—brain cancer	0.00131	0.0165	CbGeAlD
Ponatinib—TEK—blood vessel—brain cancer	0.0012	0.0152	CbGeAlD
Ponatinib—FGFR2—hindbrain—brain cancer	0.0012	0.0151	CbGeAlD
Ponatinib—SRC—endothelium—brain cancer	0.00116	0.0146	CbGeAlD
Ponatinib—FGFR4—pituitary gland—brain cancer	0.00111	0.014	CbGeAlD
Ponatinib—SRC—blood vessel—brain cancer	0.00107	0.0135	CbGeAlD
Ponatinib—KDR—endothelium—brain cancer	0.00107	0.0135	CbGeAlD
Ponatinib—KDR—blood vessel—brain cancer	0.000985	0.0124	CbGeAlD
Ponatinib—KIT—endothelium—brain cancer	0.000946	0.0119	CbGeAlD
Ponatinib—FGFR3—telencephalon—brain cancer	0.000931	0.0117	CbGeAlD
Ponatinib—KIT—blood vessel—brain cancer	0.000872	0.011	CbGeAlD
Ponatinib—FGFR4—endocrine gland—brain cancer	0.000861	0.0108	CbGeAlD
Ponatinib—FGFR4—head—brain cancer	0.00085	0.0107	CbGeAlD
Ponatinib—KIT—hindbrain—brain cancer	0.000832	0.0105	CbGeAlD
Ponatinib—Nilotinib—CYP2C9—brain cancer	0.000822	0.183	CrCbGaD
Ponatinib—BCR—telencephalon—brain cancer	0.000806	0.0102	CbGeAlD
Ponatinib—FGFR3—gonad—brain cancer	0.000777	0.00979	CbGeAlD
Ponatinib—FGFR4—central nervous system—brain cancer	0.000776	0.00977	CbGeAlD
Ponatinib—FGFR4—cerebellum—brain cancer	0.000758	0.00955	CbGeAlD
Ponatinib—FGFR3—medulla oblongata—brain cancer	0.000732	0.00922	CbGeAlD
Ponatinib—ABL1—hindbrain—brain cancer	0.000724	0.00913	CbGeAlD
Ponatinib—FGFR1—telencephalon—brain cancer	0.000717	0.00903	CbGeAlD
Ponatinib—FGFR2—brainstem—brain cancer	0.000687	0.00865	CbGeAlD
Ponatinib—Imatinib—CYP2C9—brain cancer	0.000685	0.153	CrCbGaD
Ponatinib—BCR—gonad—brain cancer	0.000672	0.00847	CbGeAlD
Ponatinib—FGFR3—midbrain—brain cancer	0.000669	0.00843	CbGeAlD
Ponatinib—FLT3—gonad—brain cancer	0.000668	0.00841	CbGeAlD
Ponatinib—BCR—pituitary gland—brain cancer	0.000656	0.00827	CbGeAlD
Ponatinib—FGFR3—spinal cord—brain cancer	0.000652	0.00822	CbGeAlD
Ponatinib—BCR—medulla oblongata—brain cancer	0.000633	0.00798	CbGeAlD
Ponatinib—FGFR4—brain—brain cancer	0.000616	0.00776	CbGeAlD
Ponatinib—FGFR2—telencephalon—brain cancer	0.00061	0.00768	CbGeAlD
Ponatinib—LYN—endocrine gland—brain cancer	0.00059	0.00744	CbGeAlD
Ponatinib—FGFR3—endocrine gland—brain cancer	0.000587	0.0074	CbGeAlD
Ponatinib—TEK—telencephalon—brain cancer	0.000584	0.00736	CbGeAlD
Ponatinib—FGFR1—pituitary gland—brain cancer	0.000584	0.00735	CbGeAlD
Ponatinib—LYN—head—brain cancer	0.000583	0.00734	CbGeAlD
Ponatinib—FGFR3—head—brain cancer	0.00058	0.00731	CbGeAlD
Ponatinib—BCR—midbrain—brain cancer	0.000579	0.00729	CbGeAlD
Ponatinib—BCR—spinal cord—brain cancer	0.000565	0.00711	CbGeAlD
Ponatinib—FGFR1—medulla oblongata—brain cancer	0.000563	0.0071	CbGeAlD
Ponatinib—LYN—central nervous system—brain cancer	0.000532	0.0067	CbGeAlD
Ponatinib—PDGFRA—telencephalon—brain cancer	0.000529	0.00667	CbGeAlD
Ponatinib—FGFR3—central nervous system—brain cancer	0.000529	0.00667	CbGeAlD
Ponatinib—RET—pituitary gland—brain cancer	0.000522	0.00658	CbGeAlD
Ponatinib—SRC—telencephalon—brain cancer	0.000519	0.00654	CbGeAlD
Ponatinib—FGFR3—cerebellum—brain cancer	0.000517	0.00652	CbGeAlD
Ponatinib—FGFR1—midbrain—brain cancer	0.000515	0.00649	CbGeAlD
Ponatinib—BCR—endocrine gland—brain cancer	0.000508	0.0064	CbGeAlD
Ponatinib—FLT3—endocrine gland—brain cancer	0.000505	0.00636	CbGeAlD
Ponatinib—RET—medulla oblongata—brain cancer	0.000504	0.00635	CbGeAlD
Ponatinib—FGFR1—spinal cord—brain cancer	0.000502	0.00633	CbGeAlD
Ponatinib—BCR—head—brain cancer	0.000502	0.00632	CbGeAlD
Ponatinib—KIT—brainstem—brain cancer	0.000477	0.00601	CbGeAlD
Ponatinib—TEK—pituitary gland—brain cancer	0.000476	0.006	CbGeAlD
Ponatinib—RET—midbrain—brain cancer	0.000461	0.00581	CbGeAlD
Ponatinib—TEK—medulla oblongata—brain cancer	0.000459	0.00579	CbGeAlD
Ponatinib—BCR—central nervous system—brain cancer	0.000458	0.00577	CbGeAlD
Ponatinib—RET—spinal cord—brain cancer	0.000449	0.00566	CbGeAlD
Ponatinib—BCR—cerebellum—brain cancer	0.000448	0.00564	CbGeAlD
Ponatinib—FLT3—cerebellum—brain cancer	0.000444	0.0056	CbGeAlD
Ponatinib—PDGFRA—gonad—brain cancer	0.000442	0.00557	CbGeAlD
Ponatinib—SRC—gonad—brain cancer	0.000433	0.00546	CbGeAlD
Ponatinib—FGFR2—spinal cord—brain cancer	0.000427	0.00538	CbGeAlD
Ponatinib—KIT—telencephalon—brain cancer	0.000423	0.00533	CbGeAlD
Ponatinib—LYN—brain—brain cancer	0.000422	0.00532	CbGeAlD
Ponatinib—FGFR3—brain—brain cancer	0.00042	0.00529	CbGeAlD
Ponatinib—TEK—midbrain—brain cancer	0.00042	0.00529	CbGeAlD
Ponatinib—ABL1—brainstem—brain cancer	0.000415	0.00523	CbGeAlD
Ponatinib—TEK—spinal cord—brain cancer	0.000409	0.00516	CbGeAlD
Ponatinib—RET—endocrine gland—brain cancer	0.000405	0.0051	CbGeAlD
Ponatinib—RET—head—brain cancer	0.000399	0.00503	CbGeAlD
Ponatinib—FGFR1—cerebellum—brain cancer	0.000398	0.00502	CbGeAlD
Ponatinib—ABCB11—endocrine gland—brain cancer	0.000395	0.00498	CbGeAlD
Ponatinib—KDR—pituitary gland—brain cancer	0.000389	0.0049	CbGeAlD
Ponatinib—FGFR2—endocrine gland—brain cancer	0.000384	0.00484	CbGeAlD
Ponatinib—FGFR2—head—brain cancer	0.00038	0.00478	CbGeAlD
Ponatinib—KDR—medulla oblongata—brain cancer	0.000375	0.00473	CbGeAlD
Ponatinib—PDGFRA—spinal cord—brain cancer	0.000371	0.00467	CbGeAlD
Ponatinib—TEK—endocrine gland—brain cancer	0.000369	0.00464	CbGeAlD
Ponatinib—ABL1—telencephalon—brain cancer	0.000368	0.00464	CbGeAlD
Ponatinib—RET—central nervous system—brain cancer	0.000365	0.00459	CbGeAlD
Ponatinib—TEK—head—brain cancer	0.000364	0.00459	CbGeAlD
Ponatinib—SRC—spinal cord—brain cancer	0.000364	0.00458	CbGeAlD
Ponatinib—BCR—brain—brain cancer	0.000364	0.00458	CbGeAlD
Ponatinib—RET—cerebellum—brain cancer	0.000356	0.00449	CbGeAlD
Ponatinib—KIT—gonad—brain cancer	0.000353	0.00445	CbGeAlD
Ponatinib—FGFR2—central nervous system—brain cancer	0.000346	0.00437	CbGeAlD
Ponatinib—KIT—pituitary gland—brain cancer	0.000345	0.00434	CbGeAlD
Ponatinib—KDR—midbrain—brain cancer	0.000343	0.00432	CbGeAlD
Ponatinib—FGFR2—cerebellum—brain cancer	0.000339	0.00427	CbGeAlD
Ponatinib—KDR—spinal cord—brain cancer	0.000335	0.00422	CbGeAlD
Ponatinib—PDGFRA—endocrine gland—brain cancer	0.000334	0.00421	CbGeAlD
Ponatinib—KIT—medulla oblongata—brain cancer	0.000333	0.00419	CbGeAlD
Ponatinib—TEK—central nervous system—brain cancer	0.000332	0.00419	CbGeAlD
Ponatinib—PDGFRA—head—brain cancer	0.00033	0.00415	CbGeAlD
Ponatinib—SRC—endocrine gland—brain cancer	0.000327	0.00413	CbGeAlD
Ponatinib—TEK—cerebellum—brain cancer	0.000325	0.00409	CbGeAlD
Ponatinib—FGFR1—brain—brain cancer	0.000323	0.00408	CbGeAlD
Ponatinib—SRC—head—brain cancer	0.000323	0.00407	CbGeAlD
Ponatinib—Chills—Procarbazine—brain cancer	0.000319	0.00295	CcSEcCtD
Ponatinib—Arrhythmia—Procarbazine—brain cancer	0.000318	0.00294	CcSEcCtD
Ponatinib—Body temperature increased—Lomustine—brain cancer	0.000315	0.00291	CcSEcCtD
Ponatinib—Alopecia—Procarbazine—brain cancer	0.000314	0.00291	CcSEcCtD
Ponatinib—CYP2D6—hindbrain—brain cancer	0.000313	0.00395	CbGeAlD
Ponatinib—Face oedema—Carmustine—brain cancer	0.000311	0.00287	CcSEcCtD
Ponatinib—ABL1—gonad—brain cancer	0.000308	0.00387	CbGeAlD
Ponatinib—Infestation NOS—Hydroxyurea—brain cancer	0.000307	0.00284	CcSEcCtD
Ponatinib—Infestation—Hydroxyurea—brain cancer	0.000307	0.00284	CcSEcCtD
Ponatinib—KIT—midbrain—brain cancer	0.000304	0.00383	CbGeAlD
Ponatinib—KDR—endocrine gland—brain cancer	0.000301	0.0038	CbGeAlD
Ponatinib—PDGFRA—central nervous system—brain cancer	0.000301	0.00379	CbGeAlD
Ponatinib—Neuropathy peripheral—Hydroxyurea—brain cancer	0.000301	0.00278	CcSEcCtD
Ponatinib—Face oedema—Temozolomide—brain cancer	0.0003	0.00278	CcSEcCtD
Ponatinib—ABL1—pituitary gland—brain cancer	0.0003	0.00378	CbGeAlD
Ponatinib—Stomatitis—Hydroxyurea—brain cancer	0.000299	0.00277	CcSEcCtD
Ponatinib—KDR—head—brain cancer	0.000297	0.00375	CbGeAlD
Ponatinib—Sepsis—Etoposide—brain cancer	0.000297	0.00275	CcSEcCtD
Ponatinib—KIT—spinal cord—brain cancer	0.000297	0.00374	CbGeAlD
Ponatinib—SRC—central nervous system—brain cancer	0.000295	0.00372	CbGeAlD
Ponatinib—PDGFRA—cerebellum—brain cancer	0.000294	0.00371	CbGeAlD
Ponatinib—Hypokalaemia—Carmustine—brain cancer	0.000293	0.00271	CcSEcCtD
Ponatinib—Hepatobiliary disease—Hydroxyurea—brain cancer	0.00029	0.00268	CcSEcCtD
Ponatinib—ABL1—medulla oblongata—brain cancer	0.00029	0.00365	CbGeAlD
Ponatinib—RET—brain—brain cancer	0.000289	0.00365	CbGeAlD
Ponatinib—Dehydration—Temozolomide—brain cancer	0.000289	0.00267	CcSEcCtD
Ponatinib—SRC—cerebellum—brain cancer	0.000288	0.00363	CbGeAlD
Ponatinib—Anaemia—Procarbazine—brain cancer	0.000286	0.00265	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Etoposide—brain cancer	0.000286	0.00265	CcSEcCtD
Ponatinib—Dry skin—Temozolomide—brain cancer	0.000285	0.00264	CcSEcCtD
Ponatinib—Hypokalaemia—Temozolomide—brain cancer	0.000283	0.00262	CcSEcCtD
Ponatinib—Breast disorder—Temozolomide—brain cancer	0.000281	0.0026	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.00028	0.00259	CcSEcCtD
Ponatinib—Leukopenia—Procarbazine—brain cancer	0.000277	0.00256	CcSEcCtD
Ponatinib—Haemoglobin—Hydroxyurea—brain cancer	0.000277	0.00256	CcSEcCtD
Ponatinib—Haemorrhage—Hydroxyurea—brain cancer	0.000275	0.00255	CcSEcCtD
Ponatinib—FGFR2—brain—brain cancer	0.000275	0.00347	CbGeAlD
Ponatinib—Cardiac failure congestive—Etoposide—brain cancer	0.000274	0.00254	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000274	0.00254	CcSEcCtD
Ponatinib—KDR—central nervous system—brain cancer	0.000271	0.00342	CbGeAlD
Ponatinib—Abdominal distension—Temozolomide—brain cancer	0.00027	0.0025	CcSEcCtD
Ponatinib—Cough—Procarbazine—brain cancer	0.00027	0.0025	CcSEcCtD
Ponatinib—Hypertension—Procarbazine—brain cancer	0.000267	0.00247	CcSEcCtD
Ponatinib—KIT—endocrine gland—brain cancer	0.000267	0.00336	CbGeAlD
Ponatinib—KDR—cerebellum—brain cancer	0.000265	0.00334	CbGeAlD
Ponatinib—ABL1—midbrain—brain cancer	0.000265	0.00333	CbGeAlD
Ponatinib—Pancytopenia—Carmustine—brain cancer	0.000264	0.00244	CcSEcCtD
Ponatinib—TEK—brain—brain cancer	0.000264	0.00332	CbGeAlD
Ponatinib—Arthralgia—Procarbazine—brain cancer	0.000264	0.00244	CcSEcCtD
Ponatinib—Myalgia—Procarbazine—brain cancer	0.000264	0.00244	CcSEcCtD
Ponatinib—KIT—head—brain cancer	0.000264	0.00332	CbGeAlD
Ponatinib—Neutropenia—Carmustine—brain cancer	0.00026	0.00241	CcSEcCtD
Ponatinib—ABL1—spinal cord—brain cancer	0.000258	0.00325	CbGeAlD
Ponatinib—Dry mouth—Procarbazine—brain cancer	0.000258	0.00239	CcSEcCtD
Ponatinib—Pancytopenia—Temozolomide—brain cancer	0.000255	0.00236	CcSEcCtD
Ponatinib—Cardiac failure—Etoposide—brain cancer	0.000255	0.00236	CcSEcCtD
Ponatinib—Vomiting—Lomustine—brain cancer	0.000253	0.00234	CcSEcCtD
Ponatinib—Oedema—Procarbazine—brain cancer	0.000253	0.00234	CcSEcCtD
Ponatinib—Neutropenia—Temozolomide—brain cancer	0.000251	0.00232	CcSEcCtD
Ponatinib—Infection—Procarbazine—brain cancer	0.000251	0.00232	CcSEcCtD
Ponatinib—Hyperglycaemia—Carmustine—brain cancer	0.000251	0.00232	CcSEcCtD
Ponatinib—Angiopathy—Hydroxyurea—brain cancer	0.00025	0.00231	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Temozolomide—brain cancer	0.00025	0.00231	CcSEcCtD
Ponatinib—Pneumonia—Carmustine—brain cancer	0.000249	0.00231	CcSEcCtD
Ponatinib—Erectile dysfunction—Temozolomide—brain cancer	0.000247	0.00229	CcSEcCtD
Ponatinib—Thrombocytopenia—Procarbazine—brain cancer	0.000247	0.00229	CcSEcCtD
Ponatinib—Chills—Hydroxyurea—brain cancer	0.000247	0.00229	CcSEcCtD
Ponatinib—Hyperhidrosis—Procarbazine—brain cancer	0.000244	0.00226	CcSEcCtD
Ponatinib—Alopecia—Hydroxyurea—brain cancer	0.000243	0.00225	CcSEcCtD
Ponatinib—Weight decreased—Temozolomide—brain cancer	0.000243	0.00225	CcSEcCtD
Ponatinib—Neuropathy peripheral—Carmustine—brain cancer	0.000243	0.00225	CcSEcCtD
Ponatinib—Hyperglycaemia—Temozolomide—brain cancer	0.000242	0.00224	CcSEcCtD
Ponatinib—Stomatitis—Carmustine—brain cancer	0.000242	0.00224	CcSEcCtD
Ponatinib—Urinary tract infection—Carmustine—brain cancer	0.000241	0.00223	CcSEcCtD
Ponatinib—Pneumonia—Temozolomide—brain cancer	0.000241	0.00223	CcSEcCtD
Ponatinib—KIT—central nervous system—brain cancer	0.000241	0.00303	CbGeAlD
Ponatinib—Erythema—Hydroxyurea—brain cancer	0.00024	0.00222	CcSEcCtD
Ponatinib—Infestation NOS—Temozolomide—brain cancer	0.00024	0.00222	CcSEcCtD
Ponatinib—Infestation—Temozolomide—brain cancer	0.00024	0.00222	CcSEcCtD
Ponatinib—PDGFRA—brain—brain cancer	0.000239	0.00301	CbGeAlD
Ponatinib—Nausea—Lomustine—brain cancer	0.000236	0.00219	CcSEcCtD
Ponatinib—ABCB1—blood vessel—brain cancer	0.000236	0.00298	CbGeAlD
Ponatinib—KIT—cerebellum—brain cancer	0.000235	0.00296	CbGeAlD
Ponatinib—Neuropathy peripheral—Temozolomide—brain cancer	0.000235	0.00217	CcSEcCtD
Ponatinib—SRC—brain—brain cancer	0.000234	0.00295	CbGeAlD
Ponatinib—Stomatitis—Temozolomide—brain cancer	0.000234	0.00216	CcSEcCtD
Ponatinib—Urinary tract infection—Temozolomide—brain cancer	0.000233	0.00215	CcSEcCtD
Ponatinib—ABL1—endocrine gland—brain cancer	0.000232	0.00293	CbGeAlD
Ponatinib—ABCG2—telencephalon—brain cancer	0.000232	0.00293	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00023	0.00213	CcSEcCtD
Ponatinib—ABL1—head—brain cancer	0.000229	0.00289	CbGeAlD
Ponatinib—Insomnia—Procarbazine—brain cancer	0.000229	0.00211	CcSEcCtD
Ponatinib—Paraesthesia—Procarbazine—brain cancer	0.000227	0.0021	CcSEcCtD
Ponatinib—Hepatobiliary disease—Temozolomide—brain cancer	0.000227	0.0021	CcSEcCtD
Ponatinib—Haemoglobin—Carmustine—brain cancer	0.000224	0.00207	CcSEcCtD
Ponatinib—Haemorrhage—Carmustine—brain cancer	0.000223	0.00206	CcSEcCtD
Ponatinib—Anaemia—Hydroxyurea—brain cancer	0.000221	0.00205	CcSEcCtD
Ponatinib—Hypoaesthesia—Carmustine—brain cancer	0.000221	0.00205	CcSEcCtD
Ponatinib—Decreased appetite—Procarbazine—brain cancer	0.00022	0.00203	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000219	0.00203	CcSEcCtD
Ponatinib—Oedema peripheral—Carmustine—brain cancer	0.000219	0.00203	CcSEcCtD
Ponatinib—Connective tissue disorder—Carmustine—brain cancer	0.000219	0.00202	CcSEcCtD
Ponatinib—Fatigue—Procarbazine—brain cancer	0.000218	0.00202	CcSEcCtD
Ponatinib—Haemoglobin—Temozolomide—brain cancer	0.000216	0.002	CcSEcCtD
Ponatinib—Constipation—Procarbazine—brain cancer	0.000216	0.002	CcSEcCtD
Ponatinib—Pain—Procarbazine—brain cancer	0.000216	0.002	CcSEcCtD
Ponatinib—KDR—brain—brain cancer	0.000216	0.00272	CbGeAlD
Ponatinib—Haemorrhage—Temozolomide—brain cancer	0.000215	0.00199	CcSEcCtD
Ponatinib—Leukopenia—Hydroxyurea—brain cancer	0.000214	0.00198	CcSEcCtD
Ponatinib—Visual impairment—Carmustine—brain cancer	0.000214	0.00198	CcSEcCtD
Ponatinib—Hypoaesthesia—Temozolomide—brain cancer	0.000214	0.00198	CcSEcCtD
Ponatinib—Oedema peripheral—Temozolomide—brain cancer	0.000212	0.00196	CcSEcCtD
Ponatinib—Connective tissue disorder—Temozolomide—brain cancer	0.000211	0.00196	CcSEcCtD
Ponatinib—ABL1—central nervous system—brain cancer	0.000209	0.00264	CbGeAlD
Ponatinib—Eye disorder—Carmustine—brain cancer	0.000208	0.00192	CcSEcCtD
Ponatinib—Visual impairment—Temozolomide—brain cancer	0.000207	0.00192	CcSEcCtD
Ponatinib—Gastrointestinal pain—Procarbazine—brain cancer	0.000207	0.00191	CcSEcCtD
Ponatinib—Flushing—Carmustine—brain cancer	0.000207	0.00191	CcSEcCtD
Ponatinib—ABL1—cerebellum—brain cancer	0.000205	0.00258	CbGeAlD
Ponatinib—Pancytopenia—Etoposide—brain cancer	0.000204	0.00189	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000203	0.00187	CcSEcCtD
Ponatinib—Neutropenia—Etoposide—brain cancer	0.000201	0.00186	CcSEcCtD
Ponatinib—Eye disorder—Temozolomide—brain cancer	0.000201	0.00186	CcSEcCtD
Ponatinib—Abdominal pain—Procarbazine—brain cancer	0.0002	0.00185	CcSEcCtD
Ponatinib—Body temperature increased—Procarbazine—brain cancer	0.0002	0.00185	CcSEcCtD
Ponatinib—Flushing—Temozolomide—brain cancer	0.0002	0.00185	CcSEcCtD
Ponatinib—Cardiac disorder—Temozolomide—brain cancer	0.0002	0.00185	CcSEcCtD
Ponatinib—Arrhythmia—Carmustine—brain cancer	0.000199	0.00184	CcSEcCtD
Ponatinib—Alopecia—Carmustine—brain cancer	0.000197	0.00182	CcSEcCtD
Ponatinib—Oedema—Hydroxyurea—brain cancer	0.000196	0.00181	CcSEcCtD
Ponatinib—Angiopathy—Temozolomide—brain cancer	0.000195	0.00181	CcSEcCtD
Ponatinib—Mental disorder—Carmustine—brain cancer	0.000195	0.0018	CcSEcCtD
Ponatinib—CYP2C8—pituitary gland—brain cancer	0.000195	0.00245	CbGeAlD
Ponatinib—Infection—Hydroxyurea—brain cancer	0.000194	0.0018	CcSEcCtD
Ponatinib—Mediastinal disorder—Temozolomide—brain cancer	0.000194	0.00179	CcSEcCtD
Ponatinib—Erythema—Carmustine—brain cancer	0.000194	0.00179	CcSEcCtD
Ponatinib—Malnutrition—Carmustine—brain cancer	0.000194	0.00179	CcSEcCtD
Ponatinib—Chills—Temozolomide—brain cancer	0.000193	0.00179	CcSEcCtD
Ponatinib—Pneumonia—Etoposide—brain cancer	0.000193	0.00178	CcSEcCtD
Ponatinib—Nervous system disorder—Hydroxyurea—brain cancer	0.000192	0.00177	CcSEcCtD
Ponatinib—Infestation NOS—Etoposide—brain cancer	0.000192	0.00177	CcSEcCtD
Ponatinib—Infestation—Etoposide—brain cancer	0.000192	0.00177	CcSEcCtD
Ponatinib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000191	0.00177	CcSEcCtD
Ponatinib—KIT—brain—brain cancer	0.000191	0.00241	CbGeAlD
Ponatinib—Alopecia—Temozolomide—brain cancer	0.00019	0.00176	CcSEcCtD
Ponatinib—Skin disorder—Hydroxyurea—brain cancer	0.00019	0.00176	CcSEcCtD
Ponatinib—ABCG2—pituitary gland—brain cancer	0.000189	0.00238	CbGeAlD
Ponatinib—Acute coronary syndrome—Etoposide—brain cancer	0.000189	0.00175	CcSEcCtD
Ponatinib—Mental disorder—Temozolomide—brain cancer	0.000188	0.00174	CcSEcCtD
Ponatinib—Neuropathy peripheral—Etoposide—brain cancer	0.000188	0.00174	CcSEcCtD
Ponatinib—Myocardial infarction—Etoposide—brain cancer	0.000188	0.00174	CcSEcCtD
Ponatinib—Back pain—Carmustine—brain cancer	0.000187	0.00173	CcSEcCtD
Ponatinib—Erythema—Temozolomide—brain cancer	0.000187	0.00173	CcSEcCtD
Ponatinib—Malnutrition—Temozolomide—brain cancer	0.000187	0.00173	CcSEcCtD
Ponatinib—Stomatitis—Etoposide—brain cancer	0.000187	0.00173	CcSEcCtD
Ponatinib—Jaundice—Etoposide—brain cancer	0.000187	0.00173	CcSEcCtD
Ponatinib—ABCG2—medulla oblongata—brain cancer	0.000183	0.0023	CbGeAlD
Ponatinib—Vision blurred—Carmustine—brain cancer	0.000183	0.00169	CcSEcCtD
Ponatinib—Asthenia—Procarbazine—brain cancer	0.000181	0.00168	CcSEcCtD
Ponatinib—Hepatobiliary disease—Etoposide—brain cancer	0.000181	0.00168	CcSEcCtD
Ponatinib—Back pain—Temozolomide—brain cancer	0.000181	0.00168	CcSEcCtD
Ponatinib—CYP2D6—brainstem—brain cancer	0.000179	0.00226	CbGeAlD
Ponatinib—Anaemia—Carmustine—brain cancer	0.000179	0.00166	CcSEcCtD
Ponatinib—Pruritus—Procarbazine—brain cancer	0.000179	0.00165	CcSEcCtD
Ponatinib—Vision blurred—Temozolomide—brain cancer	0.000176	0.00163	CcSEcCtD
Ponatinib—Dyspnoea—Hydroxyurea—brain cancer	0.000174	0.00161	CcSEcCtD
Ponatinib—Leukopenia—Carmustine—brain cancer	0.000173	0.0016	CcSEcCtD
Ponatinib—Anaemia—Temozolomide—brain cancer	0.000173	0.0016	CcSEcCtD
Ponatinib—Diarrhoea—Procarbazine—brain cancer	0.000173	0.0016	CcSEcCtD
Ponatinib—Dyspepsia—Hydroxyurea—brain cancer	0.000172	0.00159	CcSEcCtD
Ponatinib—Hypoaesthesia—Etoposide—brain cancer	0.000171	0.00158	CcSEcCtD
Ponatinib—Decreased appetite—Hydroxyurea—brain cancer	0.00017	0.00157	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000169	0.00156	CcSEcCtD
Ponatinib—Fatigue—Hydroxyurea—brain cancer	0.000169	0.00156	CcSEcCtD
Ponatinib—Leukopenia—Temozolomide—brain cancer	0.000168	0.00155	CcSEcCtD
Ponatinib—Hypertension—Carmustine—brain cancer	0.000167	0.00155	CcSEcCtD
Ponatinib—Pain—Hydroxyurea—brain cancer	0.000167	0.00155	CcSEcCtD
Ponatinib—Constipation—Hydroxyurea—brain cancer	0.000167	0.00155	CcSEcCtD
Ponatinib—Dizziness—Procarbazine—brain cancer	0.000167	0.00155	CcSEcCtD
Ponatinib—ABCG2—midbrain—brain cancer	0.000167	0.0021	CbGeAlD
Ponatinib—ABL1—brain—brain cancer	0.000166	0.0021	CbGeAlD
Ponatinib—Myalgia—Carmustine—brain cancer	0.000165	0.00153	CcSEcCtD
Ponatinib—Cough—Temozolomide—brain cancer	0.000163	0.00151	CcSEcCtD
Ponatinib—ABCG2—spinal cord—brain cancer	0.000163	0.00205	CbGeAlD
Ponatinib—Hypertension—Temozolomide—brain cancer	0.000162	0.0015	CcSEcCtD
Ponatinib—Eye disorder—Etoposide—brain cancer	0.000161	0.00149	CcSEcCtD
Ponatinib—Vomiting—Procarbazine—brain cancer	0.000161	0.00149	CcSEcCtD
Ponatinib—Cardiac disorder—Etoposide—brain cancer	0.00016	0.00148	CcSEcCtD
Ponatinib—Flushing—Etoposide—brain cancer	0.00016	0.00148	CcSEcCtD
Ponatinib—Arthralgia—Temozolomide—brain cancer	0.000159	0.00147	CcSEcCtD
Ponatinib—Myalgia—Temozolomide—brain cancer	0.000159	0.00147	CcSEcCtD
Ponatinib—Rash—Procarbazine—brain cancer	0.000159	0.00147	CcSEcCtD
Ponatinib—CYP2D6—telencephalon—brain cancer	0.000159	0.00201	CbGeAlD
Ponatinib—Dermatitis—Procarbazine—brain cancer	0.000159	0.00147	CcSEcCtD
Ponatinib—Headache—Procarbazine—brain cancer	0.000158	0.00146	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000158	0.00146	CcSEcCtD
Ponatinib—Oedema—Carmustine—brain cancer	0.000158	0.00146	CcSEcCtD
Ponatinib—Infection—Carmustine—brain cancer	0.000157	0.00145	CcSEcCtD
Ponatinib—Angiopathy—Etoposide—brain cancer	0.000156	0.00144	CcSEcCtD
Ponatinib—Dry mouth—Temozolomide—brain cancer	0.000156	0.00144	CcSEcCtD
Ponatinib—Mediastinal disorder—Etoposide—brain cancer	0.000155	0.00143	CcSEcCtD
Ponatinib—Thrombocytopenia—Carmustine—brain cancer	0.000155	0.00143	CcSEcCtD
Ponatinib—Body temperature increased—Hydroxyurea—brain cancer	0.000155	0.00143	CcSEcCtD
Ponatinib—Chills—Etoposide—brain cancer	0.000154	0.00143	CcSEcCtD
Ponatinib—Oedema—Temozolomide—brain cancer	0.000153	0.00141	CcSEcCtD
Ponatinib—Alopecia—Etoposide—brain cancer	0.000152	0.00141	CcSEcCtD
Ponatinib—Infection—Temozolomide—brain cancer	0.000152	0.0014	CcSEcCtD
Ponatinib—CYP2C8—endocrine gland—brain cancer	0.000151	0.0019	CbGeAlD
Ponatinib—Nausea—Procarbazine—brain cancer	0.00015	0.00139	CcSEcCtD
Ponatinib—Nervous system disorder—Temozolomide—brain cancer	0.00015	0.00139	CcSEcCtD
Ponatinib—Thrombocytopenia—Temozolomide—brain cancer	0.00015	0.00138	CcSEcCtD
Ponatinib—Skin disorder—Temozolomide—brain cancer	0.000148	0.00137	CcSEcCtD
Ponatinib—Hyperhidrosis—Temozolomide—brain cancer	0.000148	0.00137	CcSEcCtD
Ponatinib—Back pain—Etoposide—brain cancer	0.000145	0.00134	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000144	0.00133	CcSEcCtD
Ponatinib—Muscle spasms—Etoposide—brain cancer	0.000144	0.00133	CcSEcCtD
Ponatinib—Insomnia—Carmustine—brain cancer	0.000143	0.00132	CcSEcCtD
Ponatinib—Paraesthesia—Carmustine—brain cancer	0.000142	0.00131	CcSEcCtD
Ponatinib—Dyspnoea—Carmustine—brain cancer	0.000141	0.0013	CcSEcCtD
Ponatinib—Asthenia—Hydroxyurea—brain cancer	0.00014	0.0013	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000139	0.00129	CcSEcCtD
Ponatinib—Anaemia—Etoposide—brain cancer	0.000138	0.00128	CcSEcCtD
Ponatinib—Insomnia—Temozolomide—brain cancer	0.000138	0.00128	CcSEcCtD
Ponatinib—Decreased appetite—Carmustine—brain cancer	0.000137	0.00127	CcSEcCtD
Ponatinib—Paraesthesia—Temozolomide—brain cancer	0.000137	0.00127	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Carmustine—brain cancer	0.000136	0.00126	CcSEcCtD
Ponatinib—Dyspnoea—Temozolomide—brain cancer	0.000136	0.00126	CcSEcCtD
Ponatinib—CYP3A5—endocrine gland—brain cancer	0.000136	0.00171	CbGeAlD
Ponatinib—Pain—Carmustine—brain cancer	0.000135	0.00125	CcSEcCtD
Ponatinib—Constipation—Carmustine—brain cancer	0.000135	0.00125	CcSEcCtD
Ponatinib—Dyspepsia—Temozolomide—brain cancer	0.000134	0.00124	CcSEcCtD
Ponatinib—Leukopenia—Etoposide—brain cancer	0.000134	0.00124	CcSEcCtD
Ponatinib—Diarrhoea—Hydroxyurea—brain cancer	0.000134	0.00124	CcSEcCtD
Ponatinib—Decreased appetite—Temozolomide—brain cancer	0.000133	0.00123	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Temozolomide—brain cancer	0.000132	0.00122	CcSEcCtD
Ponatinib—Fatigue—Temozolomide—brain cancer	0.000132	0.00122	CcSEcCtD
Ponatinib—Cough—Etoposide—brain cancer	0.000131	0.00121	CcSEcCtD
Ponatinib—Constipation—Temozolomide—brain cancer	0.000131	0.00121	CcSEcCtD
Ponatinib—Pain—Temozolomide—brain cancer	0.000131	0.00121	CcSEcCtD
Ponatinib—Hypertension—Etoposide—brain cancer	0.000129	0.0012	CcSEcCtD
Ponatinib—Dizziness—Hydroxyurea—brain cancer	0.000129	0.0012	CcSEcCtD
Ponatinib—Gastrointestinal pain—Carmustine—brain cancer	0.000129	0.0012	CcSEcCtD
Ponatinib—ABCG2—cerebellum—brain cancer	0.000129	0.00163	CbGeAlD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000127	0.00117	CcSEcCtD
Ponatinib—Body temperature increased—Carmustine—brain cancer	0.000125	0.00116	CcSEcCtD
Ponatinib—Abdominal pain—Carmustine—brain cancer	0.000125	0.00116	CcSEcCtD
Ponatinib—Gastrointestinal pain—Temozolomide—brain cancer	0.000125	0.00116	CcSEcCtD
Ponatinib—Vomiting—Hydroxyurea—brain cancer	0.000124	0.00115	CcSEcCtD
Ponatinib—Rash—Hydroxyurea—brain cancer	0.000123	0.00114	CcSEcCtD
Ponatinib—Dermatitis—Hydroxyurea—brain cancer	0.000123	0.00114	CcSEcCtD
Ponatinib—Headache—Hydroxyurea—brain cancer	0.000123	0.00113	CcSEcCtD
Ponatinib—Infection—Etoposide—brain cancer	0.000121	0.00112	CcSEcCtD
Ponatinib—Body temperature increased—Temozolomide—brain cancer	0.000121	0.00112	CcSEcCtD
Ponatinib—Abdominal pain—Temozolomide—brain cancer	0.000121	0.00112	CcSEcCtD
Ponatinib—Thrombocytopenia—Etoposide—brain cancer	0.00012	0.00111	CcSEcCtD
Ponatinib—Skin disorder—Etoposide—brain cancer	0.000119	0.0011	CcSEcCtD
Ponatinib—Hyperhidrosis—Etoposide—brain cancer	0.000118	0.00109	CcSEcCtD
Ponatinib—Nausea—Hydroxyurea—brain cancer	0.000116	0.00107	CcSEcCtD
Ponatinib—ABCB1—telencephalon—brain cancer	0.000115	0.00144	CbGeAlD
Ponatinib—Asthenia—Carmustine—brain cancer	0.000113	0.00105	CcSEcCtD
Ponatinib—Paraesthesia—Etoposide—brain cancer	0.00011	0.00102	CcSEcCtD
Ponatinib—Asthenia—Temozolomide—brain cancer	0.00011	0.00101	CcSEcCtD
Ponatinib—Dyspnoea—Etoposide—brain cancer	0.000109	0.00101	CcSEcCtD
Ponatinib—Diarrhoea—Carmustine—brain cancer	0.000108	0.001	CcSEcCtD
Ponatinib—Pruritus—Temozolomide—brain cancer	0.000108	0.001	CcSEcCtD
Ponatinib—CYP2C8—brain—brain cancer	0.000108	0.00136	CbGeAlD
Ponatinib—Decreased appetite—Etoposide—brain cancer	0.000106	0.000983	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Etoposide—brain cancer	0.000106	0.000977	CcSEcCtD
Ponatinib—Fatigue—Etoposide—brain cancer	0.000105	0.000975	CcSEcCtD
Ponatinib—ABCG2—brain—brain cancer	0.000105	0.00132	CbGeAlD
Ponatinib—Dizziness—Carmustine—brain cancer	0.000105	0.000967	CcSEcCtD
Ponatinib—Pain—Etoposide—brain cancer	0.000105	0.000967	CcSEcCtD
Ponatinib—Constipation—Etoposide—brain cancer	0.000105	0.000967	CcSEcCtD
Ponatinib—Diarrhoea—Temozolomide—brain cancer	0.000105	0.000967	CcSEcCtD
Ponatinib—CYP3A4—endocrine gland—brain cancer	0.000102	0.00129	CbGeAlD
Ponatinib—Dizziness—Temozolomide—brain cancer	0.000101	0.000935	CcSEcCtD
Ponatinib—Vomiting—Carmustine—brain cancer	0.000101	0.00093	CcSEcCtD
Ponatinib—CYP2D6—endocrine gland—brain cancer	0.0001	0.00127	CbGeAlD
Ponatinib—Gastrointestinal pain—Etoposide—brain cancer	0.0001	0.000925	CcSEcCtD
Ponatinib—Rash—Carmustine—brain cancer	9.97e-05	0.000922	CcSEcCtD
Ponatinib—Dermatitis—Carmustine—brain cancer	9.96e-05	0.000921	CcSEcCtD
Ponatinib—CYP2D6—head—brain cancer	9.92e-05	0.00125	CbGeAlD
Ponatinib—Headache—Carmustine—brain cancer	9.9e-05	0.000916	CcSEcCtD
Ponatinib—Vomiting—Temozolomide—brain cancer	9.71e-05	0.000899	CcSEcCtD
Ponatinib—Body temperature increased—Etoposide—brain cancer	9.66e-05	0.000894	CcSEcCtD
Ponatinib—Abdominal pain—Etoposide—brain cancer	9.66e-05	0.000894	CcSEcCtD
Ponatinib—Rash—Temozolomide—brain cancer	9.63e-05	0.000891	CcSEcCtD
Ponatinib—Dermatitis—Temozolomide—brain cancer	9.62e-05	0.00089	CcSEcCtD
Ponatinib—Headache—Temozolomide—brain cancer	9.57e-05	0.000886	CcSEcCtD
Ponatinib—ABCB1—gonad—brain cancer	9.56e-05	0.0012	CbGeAlD
Ponatinib—Nausea—Carmustine—brain cancer	9.39e-05	0.000869	CcSEcCtD
Ponatinib—ABCB1—pituitary gland—brain cancer	9.33e-05	0.00118	CbGeAlD
Ponatinib—CYP3A4—central nervous system—brain cancer	9.2e-05	0.00116	CbGeAlD
Ponatinib—Nausea—Temozolomide—brain cancer	9.08e-05	0.00084	CcSEcCtD
Ponatinib—CYP2D6—central nervous system—brain cancer	9.05e-05	0.00114	CbGeAlD
Ponatinib—ABCB1—medulla oblongata—brain cancer	9e-05	0.00113	CbGeAlD
Ponatinib—CYP2D6—cerebellum—brain cancer	8.85e-05	0.00111	CbGeAlD
Ponatinib—Asthenia—Etoposide—brain cancer	8.77e-05	0.000812	CcSEcCtD
Ponatinib—Pruritus—Etoposide—brain cancer	8.65e-05	0.0008	CcSEcCtD
Ponatinib—Diarrhoea—Etoposide—brain cancer	8.36e-05	0.000774	CcSEcCtD
Ponatinib—ABCB1—midbrain—brain cancer	8.23e-05	0.00104	CbGeAlD
Ponatinib—Dizziness—Etoposide—brain cancer	8.08e-05	0.000748	CcSEcCtD
Ponatinib—ABCB1—spinal cord—brain cancer	8.03e-05	0.00101	CbGeAlD
Ponatinib—Vomiting—Etoposide—brain cancer	7.77e-05	0.000719	CcSEcCtD
Ponatinib—Rash—Etoposide—brain cancer	7.71e-05	0.000713	CcSEcCtD
Ponatinib—Dermatitis—Etoposide—brain cancer	7.7e-05	0.000713	CcSEcCtD
Ponatinib—Headache—Etoposide—brain cancer	7.66e-05	0.000709	CcSEcCtD
Ponatinib—Nausea—Etoposide—brain cancer	7.26e-05	0.000672	CcSEcCtD
Ponatinib—ABCB1—endocrine gland—brain cancer	7.23e-05	0.000911	CbGeAlD
Ponatinib—CYP2D6—brain—brain cancer	7.19e-05	0.000906	CbGeAlD
Ponatinib—ABCB1—head—brain cancer	7.13e-05	0.000899	CbGeAlD
Ponatinib—ABCB1—central nervous system—brain cancer	6.51e-05	0.000821	CbGeAlD
Ponatinib—ABCB1—cerebellum—brain cancer	6.37e-05	0.000802	CbGeAlD
Ponatinib—ABCB1—brain—brain cancer	5.17e-05	0.000651	CbGeAlD
Ponatinib—SRC—Adaptive Immune System—ERBB2—brain cancer	5.77e-06	3.88e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CG—brain cancer	5.77e-06	3.88e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IRS2—brain cancer	5.76e-06	3.88e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—VEGFA—brain cancer	5.76e-06	3.87e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—EGFR—brain cancer	5.74e-06	3.86e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SPP1—brain cancer	5.71e-06	3.85e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—EGFR—brain cancer	5.71e-06	3.84e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—STAT3—brain cancer	5.7e-06	3.84e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SPP1—brain cancer	5.7e-06	3.84e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—IDH1—brain cancer	5.68e-06	3.83e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HES1—brain cancer	5.63e-06	3.79e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—MYC—brain cancer	5.59e-06	3.77e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—RELA—brain cancer	5.56e-06	3.74e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IRS2—brain cancer	5.54e-06	3.73e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—ERBB2—brain cancer	5.53e-06	3.72e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—RELA—brain cancer	5.51e-06	3.71e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—EGFR—brain cancer	5.51e-06	3.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—RELA—brain cancer	5.5e-06	3.7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—ERBB2—brain cancer	5.48e-06	3.69e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—EGFR—brain cancer	5.47e-06	3.68e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—ERBB2—brain cancer	5.47e-06	3.68e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IRS2—brain cancer	5.44e-06	3.67e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HES1—brain cancer	5.44e-06	3.66e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOTCH2—brain cancer	5.44e-06	3.66e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—ERBB2—brain cancer	5.43e-06	3.65e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PDGFRA—brain cancer	5.37e-06	3.61e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—IDH1—brain cancer	5.36e-06	3.61e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—TP53—brain cancer	5.35e-06	3.6e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—ERBB2—brain cancer	5.33e-06	3.59e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL2—brain cancer	5.33e-06	3.59e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—TP53—brain cancer	5.33e-06	3.59e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IRS2—brain cancer	5.32e-06	3.58e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.31e-06	3.58e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MYC—brain cancer	5.3e-06	3.56e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CTNNB1—brain cancer	5.26e-06	3.54e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—VEGFA—brain cancer	5.24e-06	3.53e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL2—brain cancer	5.23e-06	3.52e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—STAT3—brain cancer	5.19e-06	3.49e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VAV1—brain cancer	5.18e-06	3.49e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—EGFR—brain cancer	5.18e-06	3.49e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PDGFRA—brain cancer	5.18e-06	3.49e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IRS2—brain cancer	5.17e-06	3.48e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ENO2—brain cancer	5.16e-06	3.47e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IRS2—brain cancer	5.15e-06	3.47e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CTNNB1—brain cancer	5.14e-06	3.46e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—VEGFA—brain cancer	5.14e-06	3.46e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IRS2—brain cancer	5.1e-06	3.43e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—ERBB2—brain cancer	5.06e-06	3.41e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—CTNNB1—brain cancer	5.05e-06	3.4e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—ERBB2—brain cancer	5.05e-06	3.4e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SPP1—brain cancer	5.03e-06	3.38e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL2—brain cancer	5.01e-06	3.37e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	5.01e-06	3.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL2—brain cancer	4.97e-06	3.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL2—brain cancer	4.95e-06	3.34e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—APC—brain cancer	4.9e-06	3.3e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CG—brain cancer	4.9e-06	3.3e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CCND1—brain cancer	4.88e-06	3.29e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—RELA—brain cancer	4.85e-06	3.27e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—RELA—brain cancer	4.85e-06	3.26e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CTNNB1—brain cancer	4.84e-06	3.26e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—RELA—brain cancer	4.83e-06	3.25e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—ERBB2—brain cancer	4.82e-06	3.25e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—ERBB2—brain cancer	4.81e-06	3.24e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOTCH2—brain cancer	4.81e-06	3.24e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CG—brain cancer	4.81e-06	3.24e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—APC—brain cancer	4.81e-06	3.24e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—ERBB2—brain cancer	4.8e-06	3.23e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CTNNB1—brain cancer	4.79e-06	3.23e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2C9—brain cancer	4.79e-06	3.22e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CTNNB1—brain cancer	4.78e-06	3.22e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—CTNNB1—brain cancer	4.75e-06	3.2e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—EGFR—brain cancer	4.71e-06	3.17e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IRS2—brain cancer	4.71e-06	3.17e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—EGFR—brain cancer	4.7e-06	3.17e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—APC—brain cancer	4.7e-06	3.16e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—CTNNB1—brain cancer	4.66e-06	3.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VAV1—brain cancer	4.59e-06	3.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CG—brain cancer	4.56e-06	3.07e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—APC—brain cancer	4.56e-06	3.07e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—APC—brain cancer	4.55e-06	3.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CG—brain cancer	4.55e-06	3.06e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IRS2—brain cancer	4.55e-06	3.06e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—EGFR—brain cancer	4.52e-06	3.04e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO2—brain cancer	4.49e-06	3.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—STAT3—brain cancer	4.48e-06	3.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HES1—brain cancer	4.46e-06	3e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CTNNB1—brain cancer	4.43e-06	2.98e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CTNNB1—brain cancer	4.42e-06	2.97e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—STAT3—brain cancer	4.4e-06	2.96e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—brain cancer	4.39e-06	2.95e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL2—brain cancer	4.37e-06	2.94e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL2—brain cancer	4.36e-06	2.94e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL2—brain cancer	4.35e-06	2.93e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—brain cancer	4.35e-06	2.93e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—brain cancer	4.26e-06	2.87e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCND1—brain cancer	4.25e-06	2.86e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PDGFRA—brain cancer	4.24e-06	2.86e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO2—brain cancer	4.23e-06	2.85e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—CTNNB1—brain cancer	4.22e-06	2.84e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—STAT3—brain cancer	4.22e-06	2.84e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CTNNB1—brain cancer	4.21e-06	2.84e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CTNNB1—brain cancer	4.2e-06	2.83e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—STAT3—brain cancer	4.18e-06	2.81e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—STAT3—brain cancer	4.17e-06	2.81e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—EGFR—brain cancer	4.16e-06	2.8e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—APC—brain cancer	4.16e-06	2.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—STAT3—brain cancer	4.14e-06	2.79e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SPP1—brain cancer	4.12e-06	2.77e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—EGFR—brain cancer	4.08e-06	2.74e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BSG—brain cancer	4.07e-06	2.74e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—STAT3—brain cancer	4.07e-06	2.74e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—APC—brain cancer	4.01e-06	2.7e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CG—brain cancer	4.01e-06	2.7e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—EGFR—brain cancer	4e-06	2.69e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—EGFR—brain cancer	4e-06	2.69e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—RELA—brain cancer	3.98e-06	2.68e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—ERBB2—brain cancer	3.95e-06	2.66e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HES1—brain cancer	3.95e-06	2.66e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MYC—brain cancer	3.92e-06	2.64e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—brain cancer	3.88e-06	2.61e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—STAT3—brain cancer	3.86e-06	2.6e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—STAT3—brain cancer	3.85e-06	2.59e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MYC—brain cancer	3.85e-06	2.59e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EGFR—brain cancer	3.83e-06	2.58e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RELA—brain cancer	3.83e-06	2.58e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CG—brain cancer	3.81e-06	2.57e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ERBB2—brain cancer	3.8e-06	2.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—EGFR—brain cancer	3.8e-06	2.56e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—EGFR—brain cancer	3.79e-06	2.55e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MYC—brain cancer	3.78e-06	2.54e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EGFR—brain cancer	3.76e-06	2.53e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RELA—brain cancer	3.76e-06	2.53e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PDGFRA—brain cancer	3.76e-06	2.53e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ERBB2—brain cancer	3.73e-06	2.51e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IRS2—brain cancer	3.73e-06	2.51e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—brain cancer	3.71e-06	2.5e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EGFR—brain cancer	3.7e-06	2.49e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—STAT3—brain cancer	3.68e-06	2.48e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—STAT3—brain cancer	3.67e-06	2.47e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—STAT3—brain cancer	3.66e-06	2.46e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB2—brain cancer	3.65e-06	2.46e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SPP1—brain cancer	3.65e-06	2.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—brain cancer	3.59e-06	2.41e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—brain cancer	3.58e-06	2.41e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—brain cancer	3.58e-06	2.41e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RELA—brain cancer	3.57e-06	2.4e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RELA—brain cancer	3.56e-06	2.39e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB2—brain cancer	3.54e-06	2.39e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB2—brain cancer	3.53e-06	2.38e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—RELA—brain cancer	3.52e-06	2.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—brain cancer	3.51e-06	2.36e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—IDH1—brain cancer	3.5e-06	2.36e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB2—brain cancer	3.5e-06	2.36e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—brain cancer	3.5e-06	2.35e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CTNNB1—brain cancer	3.46e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—brain cancer	3.45e-06	2.32e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—brain cancer	3.41e-06	2.3e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—brain cancer	3.38e-06	2.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—brain cancer	3.36e-06	2.26e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—brain cancer	3.34e-06	2.25e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—brain cancer	3.34e-06	2.25e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—brain cancer	3.33e-06	2.24e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CTNNB1—brain cancer	3.33e-06	2.24e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IRS2—brain cancer	3.3e-06	2.22e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—brain cancer	3.3e-06	2.22e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CG—brain cancer	3.29e-06	2.22e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APC—brain cancer	3.29e-06	2.22e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CTNNB1—brain cancer	3.27e-06	2.2e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—brain cancer	3.23e-06	2.17e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—brain cancer	3.22e-06	2.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—brain cancer	3.21e-06	2.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—brain cancer	3.2e-06	2.16e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CTNNB1—brain cancer	3.19e-06	2.15e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—brain cancer	3.17e-06	2.13e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RELA—brain cancer	3.14e-06	2.11e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—brain cancer	3.13e-06	2.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—brain cancer	3.12e-06	2.1e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—brain cancer	3.12e-06	2.1e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CTNNB1—brain cancer	3.1e-06	2.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CTNNB1—brain cancer	3.09e-06	2.08e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CTNNB1—brain cancer	3.06e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—brain cancer	3.01e-06	2.03e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—brain cancer	2.93e-06	1.97e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APC—brain cancer	2.91e-06	1.96e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CG—brain cancer	2.91e-06	1.96e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—brain cancer	2.9e-06	1.95e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—brain cancer	2.88e-06	1.94e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—brain cancer	2.85e-06	1.92e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—brain cancer	2.83e-06	1.9e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—brain cancer	2.83e-06	1.9e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—brain cancer	2.8e-06	1.89e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—brain cancer	2.78e-06	1.87e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO2—brain cancer	2.77e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—brain cancer	2.75e-06	1.85e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—brain cancer	2.74e-06	1.84e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CG—brain cancer	2.73e-06	1.84e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—brain cancer	2.73e-06	1.84e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—brain cancer	2.73e-06	1.84e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—brain cancer	2.72e-06	1.83e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—brain cancer	2.7e-06	1.82e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—brain cancer	2.7e-06	1.81e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—brain cancer	2.69e-06	1.81e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—brain cancer	2.67e-06	1.8e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—brain cancer	2.65e-06	1.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—brain cancer	2.63e-06	1.77e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—brain cancer	2.59e-06	1.74e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—brain cancer	2.59e-06	1.74e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RELA—brain cancer	2.57e-06	1.73e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—brain cancer	2.56e-06	1.72e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—brain cancer	2.53e-06	1.7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—brain cancer	2.51e-06	1.69e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—brain cancer	2.5e-06	1.69e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—brain cancer	2.46e-06	1.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—brain cancer	2.46e-06	1.65e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—brain cancer	2.45e-06	1.65e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—brain cancer	2.42e-06	1.63e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—brain cancer	2.4e-06	1.62e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—brain cancer	2.38e-06	1.6e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—brain cancer	2.37e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—brain cancer	2.32e-06	1.56e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—brain cancer	2.29e-06	1.54e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RELA—brain cancer	2.28e-06	1.53e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—brain cancer	2.26e-06	1.52e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—brain cancer	2.26e-06	1.52e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—brain cancer	2.24e-06	1.51e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—brain cancer	2.24e-06	1.5e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—brain cancer	2.21e-06	1.49e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—brain cancer	2.21e-06	1.49e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—brain cancer	2.17e-06	1.46e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—brain cancer	2.16e-06	1.45e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—brain cancer	2.06e-06	1.39e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—brain cancer	2.06e-06	1.39e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—brain cancer	2.06e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—brain cancer	2.05e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—brain cancer	2e-06	1.35e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—brain cancer	1.98e-06	1.33e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—brain cancer	1.97e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—brain cancer	1.95e-06	1.31e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—brain cancer	1.94e-06	1.31e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—brain cancer	1.81e-06	1.22e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—brain cancer	1.81e-06	1.22e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—brain cancer	1.77e-06	1.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—brain cancer	1.74e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—brain cancer	1.73e-06	1.16e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—brain cancer	1.6e-06	1.08e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—brain cancer	1.57e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—brain cancer	1.49e-06	1e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—brain cancer	1.32e-06	8.86e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—brain cancer	1.27e-06	8.55e-06	CbGpPWpGaD
